[8-K] BioRestorative Therapies, Inc. Reports Material Event

Rhea-AI Filing Summary

BioRestorative Therapies, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The release also provided a business update and included details for a conference call to discuss the quarter. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

The filing states that the information furnished is summary information to be considered in the context of the Company’s SEC filings and other public announcements. The Company expressly furnishes the press release (it is not being filed for purposes of Section 18 of the Exchange Act) and does not incorporate the press release by reference into other registration statements unless specifically stated.

Positive

• Press release furnished announcing results for the quarter ended June 30, 2025
• Business update and conference call details were included and made available to stakeholders
• Exhibit 99.1 is provided, enabling investors to access the full press release

Negative

• No financial figures or metrics are included in the 8-K text, preventing assessment of performance from this filing alone
• Information is furnished, not filed, which limits Section 18 liability and indicates the 8-K is procedural rather than substantive

Insights

Financial Analyst

TL;DR Routine quarterly disclosure: press release issued with Q2 results, business update, and conference call; no financials included in the 8-K text.

The Company furnished a press release reporting results for the quarter ended June 30, 2025, and provided conference call logistics. Because the 8-K itself does not include any revenue, profit, cash flow, or guidance figures, the filing is a procedural disclosure rather than a standalone earnings summary. Investors must review Exhibit 99.1 and the Company’s periodic SEC filings for material financial detail. Impact: neutral pending the substance of the furnished press release.

Corporate Governance Expert

TL;DR Disclosure furnished, not filed: limited liability for Section 18; procedural compliance observed.

The 8-K clarifies that the press release is being furnished rather than filed, which limits Section 18 liability and avoids automatic incorporation by reference. This is a standard approach for distributing earnings releases and call information while preserving filing mechanics. The disclosure is complete in describing its procedural status but contains no substantive financial metrics. From a governance perspective this is routine and non-impactful absent additional material disclosures.

false000150549700015054972025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 12, 2025

BioRestorative Therapies, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-37603		30-1341024
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

40 Marcus Drive Melville, New York		11747
(Address of principal executive offices)		(Zip code)

Registrant's telephone number, including area code (631) 760-8100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	BRTX	NASDAQ Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Result of Operations and Financial Condition.

On August 12, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 (the “Press Release”).  The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the second quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto.

The information contained in the Press Release is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

See Item 2.02 above.

The information in the Press Release is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Press Release will not be incorporated by reference into any registration statement filed by the Company under the Securities Act unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Current Report on Form 8-K with respect to the Press Release is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Press Release is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number	Description
99.1	Press release, dated August 12, 2025, issued by BioRestorative Therapies, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIORESTORATIVE THERAPIES, INC.
Dated:  August 12, 2025	By:	/s/ Robert Kristal
		Robert Kristal
		Chief Financial Officer

FAQ

What did BioRestorative Therapies (BRTX) disclose in this 8-K?

The company furnished a press release announcing financial results for the quarter ended June 30, 2025, provided a business update, and included conference call details.

Is the press release included as a filed exhibit?

The press release is furnished as Exhibit 99.1; the filing states the information is furnished, not filed, for purposes of the Exchange Act.

Does the 8-K include financial results such as revenue or net income?

No. The 8-K text does not include any revenue, profit, cash flow, or numerical financial metrics; those must be obtained from Exhibit 99.1 or other filings.

Will the press release be incorporated by reference into other SEC filings?

No—the 8-K states the press release will not be incorporated by reference into registration statements unless expressly specified.

Who provided the 8-K on behalf of the company?

The Current Report was signed by the company’s Chief Financial Officer as the authorized representative for the filing.